Miacalcic Nasal 200

Miacalcic Nasal 200 belongs to groups of medications called hypocalcemic agents, primarily indicated for the treatment of postmenopausal osteoporosis in women more than five years postmenopause when alternative therapies are unsuitable. Post-menopausal osteoporosis is a medical condition that causes thinning and weakening of the bones during/after a menopausal period.

Miacalcic Nasal 200 contains Calcitonin, a human hormone that prevents bone breakdown and increases bone density (thickness). Thus it helps to treat osteoporosis in postmenopausal women.

Use Miacalcic Nasal 200 as prescribed by the doctor. Miacalcic Nasal 200 may cause certain side effects such as hypocalcemia, runny nose, nosebleed, sinus pain, application site reactions such as rhinitis (stuffy nose), epistaxis (nose bleeds) and other nasal symptoms, back pain, arthralgia (Joint pain) and headache. Most of these side effects do not require medical attention and gradually resolve over time. However, if these side effects persist longer, please consult your doctor.

Miacalcic Nasal 200 is for intranasal use only, do not inject or take it orally. Before using Miacalcic Nasal 200, inform your doctor of all your medical conditions, sensitivities, and all medications you are using. Miacalcic Nasal 200 is intended for post-menopausal women; therefore, Miacalcic Nasal 200 should not be recommended for other populations. Avoid drinking alcohol because it affects how the body absorbs calcium and vitamin D, which are essential for good bone formation.

Miacalcic Nasal 200 contains Calcitonin, a calcitonin receptor agonist that prevents the loss of bones that happens after menopause and helps to rebuild bones. Calcitonin is a hormone that the C-cells in the thyroid gland produce and release. It opposes the parathyroid hormone's action, helping regulate the blood’s calcium and phosphate levels. Miacalcic Nasal 200 works by suppressing the activity of the osteoclasts (cells that break down bone). When the osteoclasts break down bone tissue, the calcium enters the bloodstream. Miacalcic Nasal 200 lessens the amount of calcium in the blood by preventing the breakdown of bone. Thereby, Miacalcic Nasal 200 strengthens the bones and minimizes the risk of fractures. Miacalcic Nasal 200 also seems to decrease the amount of calcium the kidneys can re-absorb, lowering calcium levels further.

Before using Miacalcic Nasal 200, Inform your doctor about all your medical conditions, sensitivities, and all medications you are using. Miacalcic Nasal 200 is intended for post-menopausal women; therefore, Miacalcic Nasal 200 should not be recommended for other populations. In rare situations, individuals using Miacalcic Nasal 200 may be affected with anaphylactic shock (a sudden, severe, life-threatening allergic reaction leading to difficulty breathing); if you encounter it, stop using Miacalcic Nasal 200 and contact your doctor immediately.

• Consume calcium-rich foods like milk, yoghurt, cheese, green leafy vegetables, fish with bones such as salmon, sardines, calcium-fortified cereals and orange juice.
• Exposure to sunlight helps synthesise vitamin D, essential for strong bones and muscles.
• Eating vitamin-D-rich foods such as egg yolks, salmon, oily fish like sardines, and mackerel.
• Indulging in regular exercise to prevent bone loss. Activities include brisk walking, dancing, jogging, and strength training exercises like lifting weights and using weight machines or elastic bands.
• Engaging in activities for stress relief, such as meditation and yoga.
• Preserving a healthy weight eases pressure on the bones.
• Taking medications if one is at risk for osteoporosis.
• Quitting smoking and limiting alcohol consumption.

• Hypocalcemia has been reported. Make sure you get enough calcium and vitamin D, as recommended by the doctor.
• Nasal side effects, including severe ulceration, are possible. Nasal examinations should be done regularly.

Postmenopausal osteoporosis: Postmenopausal osteoporosis is a medical disorder that causes bone loss and weakness during and after menopause. Estrogen insufficiency increases the risk of developing osteoporosis (weak bones). The decline in oestrogen during the menopause era (45 years of age) causes more bone resorption (osteoclasts; bone disintegration) than creation (osteoblasts; new bone development), leading to osteoporosis. Osteoporosis has no symptoms in the early stages. Yet, if sufficient care is not given, it might result in shattered bones. The bones do not pain at first, and breaks in the spine's bones may go unnoticed until they cause height reduction. Bones with osteoporosis might shatter at any time, even during normal tasks such as lifting or small activities.